#NeuLogiq
LightNews LightNews
newsen.bsky.social
Cumulus Neuroscience's NeuLogiq Platform Validates Safety for Zalsupindole in Treating Major Depressive Disorder#United_States#Miami#Cumulus_Neuroscience#NeuLogiq_Platform#zalsupindole
Cumulus Neuroscience's NeuLogiq Platform Validates Safety for Zalsupindole in Treating Major Depressive Disorder
Cumulus Neuroscience showcased their NeuLogiq Platform at the ASCP 2026 Conference, confirming no cognitive impairment from the neuroplastogen zalsupindole in a Phase 1b trial.
third-news.com
May 28, 2026 at 4:03 PM
neuroscienceirl.bsky.social
🌟 Grateful to all #NSI2025 sponsors — with special thanks to Platinum Sponsor Cumulus Neuroscience and Dr. Alison Buick, who also presented CNS-101 results validating the NeuLogiq® platform for at-home #dementia monitoring (59 pts, 60 controls).

🔗 cumulusneuro.com
September 9, 2025 at 11:38 AM
longevitytech.bsky.social
NeuLogiq platform earned high marks from ALS and FTD patients using it at home, addressing a gap left by motor-only rating scales.

Link as first comment.

#longevity #geroscience #neulogiq #als #ftd
Woman wearing an EEG headset with a scientific background.
September 10, 2026 at 3:33 PM
newsen.bsky.social
Cumulus Neuroscience's NeuLogiq® Platform Shows Promise for At-Home Cognitive Assessment in ALS and FTD Patients#Ireland#ALS#Belfast#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience's NeuLogiq® Platform Shows Promise for At-Home Cognitive Assessment in ALS and FTD Patients
Cumulus Neuroscience reveals compelling results from CNS-102, indicating that NeuLogiq® can effectively assess cognitive function at home for ALS and FTD patients.
third-news.com
August 20, 2026 at 6:27 AM
newsen.bsky.social
Cumulus Neuroscience's NeuLogiq Platform: A Breakthrough for At-Home Cognitive Assessment in ALS and FTD#United_States#Dublin#Neurodegenerative_Disease#NeuLogiq#ALS-FTD_Study
Cumulus Neuroscience's NeuLogiq Platform: A Breakthrough for At-Home Cognitive Assessment in ALS and FTD
Cumulus Neuroscience's NeuLogiq platform demonstrates feasibility for at-home cognitive assessments in ALS and FTD patients, as revealed in a new study.
third-news.com
August 20, 2026 at 6:16 AM
l2plabs.bsky.social
Cumulus Neuroscience gibt die Veröffentlichung eines Artikels in der Fachzeitschrift „Scientific Reports" bekannt, der belegt, dass die NeuLogiq®-Plattform für die multimodale kognitive Beurteilung von Menschen mit ALS und FTD zu Hause geeignet und einsetzbar ist
Die endgültigen Ergebnisse der CNS-102-Studie, die in der Fachzeitschrift Scientific Reports veröffentlicht wurden, zeigen, dass die NeuLogiq®-Plattform für den Heimgebrauch erfolgreich bei Patienten mit erheblichen motorischen und kognitiven Beeinträchtigungen eingesetzt werden kann – 82...
dlvr.it
August 20, 2026 at 6:20 AM
l2plabs.bsky.social
Cumulus Neuroscience annonce la publication d'un article dans Scientific Reports démontrant que la plateforme NeuLogiq® est viable et utilisable pour l'évaluation cognitive multimodale à domicile chez les personnes atteintes de sclérose latérale amyotrophique (SLA) et de dégénérescence fronto-temporale (DFT)
Les résultats finaux de l'étude CNS-102, publiés dans la revue Scientific Reports, montrent que la plateforme NeuLogiq® à domicile peut être mise en œuvre avec succès chez des patients présentant des troubles moteurs et cognitifs importants : 82 % des participants atteints de SLA ont jugé...
dlvr.it
August 20, 2026 at 6:23 AM
newsen.bsky.social
Cumulus Neuroscience's NeuLogiq® Platform Advances At-Home Cognitive Assessments for ALS and FTD Patients#USA#Belfast#Cumulus_Neuroscience#NeuLogiq®#ALS-FTD
Cumulus Neuroscience's NeuLogiq® Platform Advances At-Home Cognitive Assessments for ALS and FTD Patients
Cumulus Neuroscience's NeuLogiq® Platform shows promise for at-home cognitive assessments in ALS and FTD patients, improving clinical trials.
third-news.com
August 18, 2026 at 4:09 PM
newsen.bsky.social
Cumulus Neuroscience's NeuLogiq Platform Revolutionizes At-Home Cognitive Assessment for ALS and FTD Patients#United_Kingdom#ALS#Belfast#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience's NeuLogiq Platform Revolutionizes At-Home Cognitive Assessment for ALS and FTD Patients
Cumulus Neuroscience's groundbreaking NeuLogiq Platform has been validated for at-home cognitive assessment in ALS and FTD, offering new hope and ease of use for patients.
third-news.com
August 18, 2026 at 3:47 PM
l2plabs.bsky.social
Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD
Final results from the CNS-102 study, published in Scientific Reports, show that the at-home NeuLogiq® Platform can be deployed successfully in patients with significant motor and cognitive impairment — with 82% of ALS participants rating the platform easy to use and 75% rating their...
dlvr.it
August 18, 2026 at 4:10 PM
newsen.bsky.social
Cumulus Neuroscience Unveils Groundbreaking Data on Alzheimer’s Trial Screening at AAIC 2026#USA#London#Cumulus_Neuroscience#NeuLogiq#Alzheimer's_Research
Cumulus Neuroscience Unveils Groundbreaking Data on Alzheimer’s Trial Screening at AAIC 2026
Cumulus Neuroscience showcased compelling data at AAIC 2026, revealing a two-minute digital task that meets clinical benchmarks for Alzheimer's trial participant selection.
third-news.com
July 15, 2026 at 2:33 PM
newsen.bsky.social
Cumulus Neuroscience's Innovative Digital Task Enhances Alzheimer's Trial Efficiency#USA#London#Cumulus_Neuroscience#NeuLogiq#Alzheimer's_Trials
Cumulus Neuroscience's Innovative Digital Task Enhances Alzheimer's Trial Efficiency
Cumulus Neuroscience unveils groundbreaking data demonstrating that its two-minute digital task surpasses clinical benchmarks in Alzheimer's trials, enhancing recruitment efficiency.
third-news.com
July 15, 2026 at 9:30 AM
l2plabs.bsky.social
Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
Across three independent studies, the NeuLogiq® Platform two-minute tablet-based Symbol Swap task delivered clinically meaningful discrimination between control, MCI and Alzheimer's dementia groups and detected blood-biomarker-defined pathology — including in clinically normal individuals...
dlvr.it
July 15, 2026 at 9:38 AM
l2plabs.bsky.social
Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
Across three independent studies, the NeuLogiq® Platform two-minute tablet-based Symbol Swap task delivered clinically meaningful discrimination between control, MCI and Alzheimer's dementia groups and detected blood-biomarker-defined pathology — including in clinically normal individuals...
dlvr.it
July 15, 2026 at 9:04 AM
newsen.bsky.social
Cumulus Neuroscience and Muse Innovate Sleep EEG Technology for Clinical Trials#London#United_Kingdom#Cumulus_Neuroscience#NeuLogiq#Muse_by_Interaxon
Cumulus Neuroscience and Muse Innovate Sleep EEG Technology for Clinical Trials
Cumulus Neuroscience and Muse by Interaxon have announced a collaboration to integrate sleep EEG technology for clinical trials. This marks a significant advancement in neuroscience research.
third-news.com
July 6, 2026 at 12:14 PM
newsen.bsky.social
Cumulus Neuroscience Unveils Promising NeuLogiq® Platform for Alzheimer's Assessment at Home#United_Kingdom#Alzheimer's_Disease#Belfast#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience Unveils Promising NeuLogiq® Platform for Alzheimer's Assessment at Home
Discover how the NeuLogiq® Platform is paving the way for at-home cognitive assessments in Alzheimer's patients, showcasing high usability and adherence.
third-news.com
June 30, 2026 at 1:33 PM
newsen.bsky.social
Revolutionizing Alzheimer’s Trials: Cumulus Neuroscience's Insights from CTAD 2025#United_States#San_Diego#Alzheimer's_Disease#Cumulus_Neuroscience#NeuLogiq
Revolutionizing Alzheimer’s Trials: Cumulus Neuroscience's Insights from CTAD 2025
Cumulus Neuroscience unveiled pivotal findings at CTAD 2025, showcasing how at-home digital endpoints enhance trial efficiency and cost-effectiveness in Alzheimer's research.
third-news.com
December 4, 2025 at 3:18 PM
newsen.bsky.social
Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences#United_Kingdom#Clinical_Trials#Amsterdam#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences
Cumulus Neuroscience has presented groundbreaking findings at prominent neuroscience events, highlighting advancements in clinical trials and digital health technology.
third-news.com
October 13, 2025 at 8:05 AM
newsen.bsky.social
Cumulus Neuroscience Welcomes Robert Ballantine to Board of Directors#United_Kingdom#Belfast#Cumulus_Neuroscience#NeuLogiq#Robert_Ballantine
Cumulus Neuroscience Welcomes Robert Ballantine to Board of Directors
Cumulus Neuroscience, a leader in digital health, announces Robert Ballantine's appointment to its board, enhancing its commitment to neuroscience innovations.
third-news.com
September 10, 2025 at 8:04 AM
newsen.bsky.social
NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials#United_States#Scottsdale,_Arizona#Cumulus_Neuroscience#Major_Depressive_Disorder#NeuLogiq_Platform
NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials
Cumulus Neuroscience presents groundbreaking findings demonstrating the NeuLogiq® Platform's ability to identify key electrophysiological signals in patients with Major Depressive Disorder, enhancing clinical trials.
third-news.com
May 29, 2025 at 12:08 PM
newsen.bsky.social
Cumulus Neuroscience Unveils Groundbreaking Findings at AD/PD 2025 Annual Meeting#None#Vienna#Alzheimer's_Disease#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience Unveils Groundbreaking Findings at AD/PD 2025 Annual Meeting
Cumulus Neuroscience presented pivotal data at the AD/PD 2025 Annual Meeting, validating its NeuLogiq® Platform for Alzheimer's and ALS-FTD assessments.
third-news.com
April 4, 2025 at 12:15 PM
neuroscienceirl.bsky.social
🧠 Could digital biomarkers transform dementia clinical trials?

Dr Alison Buick (Cumulus Neuroscience) will share results from a 1-year study of the NeuLogiq® platform for at-home monitoring in dementia:
🔗 neuroscienceireland.com/nsi-2025-dr-...
August 8, 2025 at 11:07 AM
l2plabs.bsky.social
Cumulus Neuroscience and Muse by Interaxon Bring Validated At-Home Sleep EEG to CNS Clinical Trials
Collaboration adds brain-based sleep measurement to the NeuLogiq® multi-modal platform BELFAST, Northern Ireland, DUBLIN and TORONTO, July 6, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials...
dlvr.it
July 6, 2026 at 12:03 PM
l2plabs.bsky.social
Cumulus Neuroscience Announces Publication in Frontiers in Digital Health Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home Cognitive and EEG Assessment in People Living with Mild Alzheimer's Disease Dementia
Final results from the CNS-101 study, published in Frontiers in Digital Health, show that the NeuLogiq Platform can be used successfully over a full year by patients living with mild Alzheimer's disease dementia. Patients in the study completed 99.7% of initiated sessions and maintained...
dlvr.it
June 30, 2026 at 1:02 PM
l2plabs.bsky.social
Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting
Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater separation with Alzheimer's pTau217 pathology than the benchmark Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)...
dlvr.it
April 4, 2025 at 12:03 PM